Clinical Aspects

• Age as Risk Factor for TdP
• Antiarrhythmic Drugs and QT Prolongation
• Antibiotics and QT Prolongation
• Antipsychotics and Repolarization
• Atrial Fibrillation Drugs and QT Prolongation
• Bedside aspects of QT monitoring
• Clinical management of TdP
• Drug Induced QT - Sotalol Experience
• Drug induced QT and exercise testing
• Drug-Induced QT Prolongation
• ECG screening for QT prolonging drugs
• How to measure QT
• Long QT Syndrome as Paradigm for Drug-Induced QT Prolongation
• Managing Safety of Drugs for atrial fibrillation
• Normal values for QT Not All QT
• Prolonging Drugs are Harmful
• QT Prolongation in Dialysis
• Patients QT Variability and its Application for Drug Testing
• Sex Related Differences in Torsade de Pointe
• Short QT and Drugs

Mechanisms

• Drug-Induced Transmural Dispersion of Repolarization
• ECG Restitution and its Relevance for Drug-Induced Repolarization
• Abnormalities
• Sodium Channel Abnormalities
• The electrophysiologic mechanism of TdP in drug-induced long QT syndrome
• Drugs and T wave alternans and calcium handling
• HERG channel function in LQT2 and Drug-Induced Conditions
• Ion channel Genes and Propensity to TdP
• Ion Channel Testing LQTS
• Polymorphisms and Genetic Drug testing
• Pharmacogenomics of Drug-Induced Conditions

Methods

• Digital QT analysis
• ECG Corel Lab Approach to Drug Testing
• Individual QT-RR Correction
• Novel Methods to Quantify Drug-Induced Repolarization Changes
• Pacing in Drug Testing QT measurements on screen methods
• RR Bin Approach in Repolarization Analysis

Testing Drugs

• Design of drug testing
• Duke initiative
• Preclinical Identification of torsadogenic risk
• QT Monitoring in Phase I and Phase II Studies
• QT monitoring in Phase III Studies
• QT Wearhouse
• Regulary Perspective
• Repolarization Variability in Drug-Induced Models
• Statistical Aspects of Drug Safety Testing
• Thorough QT Study
• Torsades due to methadone: Risk Management Alternatives
• What QT prolongation is of concern